Medical Devices Electrophysiology comparable sales growth measures year-over-year growth in Abbott's Electrophysiology franchise on the company's comparable basis.
Abbott reported 13.4% comparable sales growth in Electrophysiology in the second quarter of 2026.
Historical comparability requires the 2026 reclassification
Abbott transferred Amplatzer Amulet and related accessories from Structural Heart to Electrophysiology effective January 1, 2026.
The company recast the prior-year period by moving $55M of second-quarter 2025 sales into Electrophysiology.
Recast history matters to the growth rate
Without the reclassification, the reported franchise comparison would mix different product perimeters.
Read it with Structural Heart comparable growth and Medical Devices comparable growth.
Primary source: Abbott Q2 2026 earnings release filed with the SEC.
Part of the Medical Device Portfolio Growth
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- ABTOpen operating-model research →10 of 10 reviewed concepts in Medical Device Portfolio GrowthCardiovascular franchise mix6 of 6 bridge concepts supportedContinue through this bridge:Heart Failure GrowthNeuromodulation GrowthRhythm Management GrowthStructural Heart GrowthVascular Growth
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare medical device portfolio growth
Compare Electrophysiology growth while preserving Abbott's 2026 Amulet reclassification and recast prior-year base.
Explore more topics in the Financial Research Encyclopedia.